• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Neutron therapy (dT, 14 MeV) for recurrence of rectal cancer: interim analysis from Münster.

作者信息

Eising E, Pötter R, Haverkamp U, Schnepper E

机构信息

Klinik und Poliklinik für Strahlentherapie, Westfälischen Wilhelms-Universität Münster.

出版信息

Strahlenther Onkol. 1990 Jan;166(1):90-4.

PMID:1689079
Abstract

For rectal recurrent cancer and macroscopic residual disease after surgery neutron radiotherapy has been suggested to be superior to photon radiotherapy. At the d,T generator in Münster (14 MeV) 20 patients have been treated with a combined photon-/neutron-radiotherapy: two patients with residual disease after surgery: among the 18 patients with rectal recurrence 15 for pain relief; all for tumor control. Tumor resection had been carried out in five recurrent tumors. Six patients presented with distant metastases. 30 to 40 Gy photons for tumor region and potential microscopic spread with 2 Gy per fraction and 5 to 10 Gy neutrons for macroscopic tumor volume with 0.7 to 1.6 Gy per fraction were applied using multiple fields (three to five). The mean follow-up period is nine months. Pain relief was achieved in eleven of 15 patients (73%), the onset of pain was fast, the probability for a pain-free period is 46% for nine months and for survival 56% for twelve months. Side-effects were slight to moderate beside a severe subcutaneous fibrosis in two patients. The superiority of neutrons to photons in rectal recurrent cancer remains questionable and is to be proven in a prospective trial comparing different schedules for frequency, onset and duration of pain relief, tumor control, survival and side-effects.

摘要

相似文献

1
Neutron therapy (dT, 14 MeV) for recurrence of rectal cancer: interim analysis from Münster.
Strahlenther Onkol. 1990 Jan;166(1):90-4.
2
[Results of the treatment with fast neutrons (d.T 13 MeV) in recurrent rectal carcinoma].[快中子(d.T 13 MeV)治疗复发性直肠癌的结果]
Strahlenther Onkol. 1997 Jun;173(6):316-22. doi: 10.1007/BF03038914.
3
Photon-neutron therapy for recurrent colorectal cancer--follow up and preliminary results.复发性结直肠癌的光子-中子治疗——随访及初步结果
Strahlenther Onkol. 1990 Jan;166(1):95-8.
4
Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.术前超分割放化疗用于既往盆腔放疗后的局部复发性直肠癌患者:一项多中心II期研究。
Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1129-39. doi: 10.1016/j.ijrobp.2005.09.017. Epub 2006 Jan 18.
5
Neutron radiotherapy in adenoidcystic carcinoma: preliminary experience at the Münster neutron facility.腺样囊性癌的中子放射治疗:明斯特中子设施的初步经验。
Strahlenther Onkol. 1990 Jan;166(1):78-85.
6
Quantification of subcutaneous fibrosis after combined photon neutron therapy.联合光子中子治疗后皮下纤维化的定量分析。
Strahlenther Onkol. 1990 Jan;166(1):76-7.
7
Combined neutron-photon-therapy of locally recurrent rectosigmoidal tumors.
Strahlenther Onkol. 1989 Apr;165(4):327-9.
8
[3 years' experience of radiation therapy with fast neutrons on the V-120 cyclotron].[在V - 120回旋加速器上进行快中子放射治疗的3年经验]
Vopr Onkol. 1989;35(11):1341-5.
9
An interim assessment of the experience of fast neutron boost in inoperable rectal carcinomas in Orléans.
Bull Cancer. 1986;73(5):591-5.
10
Ten years of fast neutron therapy in Münster.明斯特十年快中子治疗
Bull Cancer Radiother. 1996;83 Suppl:115s-21s. doi: 10.1016/0924-4212(96)84895-x.

引用本文的文献

1
Fast and Furious: Fast Neutron Therapy in Cancer Treatment.《速度与激情:快中子疗法在癌症治疗中的应用》
Int J Part Ther. 2022 Aug 5;9(2):59-69. doi: 10.14338/IJPT-22-00017. eCollection 2022 Fall.
2
Heavy charged particles for gastrointestinal cancers.用于胃肠道癌症的重带电粒子
J Gastrointest Oncol. 2020 Feb;11(1):203-211. doi: 10.21037/jgo.2019.03.14.